Polpharma Biologics and MS Pharma Sign Licensing Agreements for ...

Polpharma Biologics and MS Pharma Sign Licensing Agreements for Proposed Vedolizumab (PB016), Ocrelizumab (PB018) and Guselkumab (PB019) Biosimilars

AMSTERDAM & ZUG, Switzerland & GDAŃSK, Poland--(BUSINESS WIRE)--Sep 2, 2025-

Polpharma Biologics signs biosimilars licensing deals with MS Pharma

According to the agreements, MS Pharma will oversee the registration, marketing along with the distribution of vedolizumab (PB016), ocrelizumab (PB018), and guselkumab (PB019) throughout MENA. Polpharma Biologics will The post Polpharma Biologics signs biosimilars licensing deals with MS Pharma appeared first on Pharmaceutical Business review.

Polpharma Biologics and MS Pharma sign licensing agreements

Polpharma Biologics has announced that it has signed licensing agreements with MS Pharma for the commercialisation of its biosimilar candidates vedolizumab (PB016), ocrelizumab (PB018) and guselkumab (PB019) in the MENA region.

Polpharma Biologics secures distribution of upcoming biosimilars - European Biotechnology Magazine

Polpharma Biologics SA and MS Pharma SA have signed licensing agreements for Polpharma's vedolizumab (PB016), ocrelizumab (PB018) and guselkumab (PB019) biosimilars in the Middle East and North Africa (MENA) region. The post Polpharma Biologics secures distribution of upcoming biosimilars appeared first on European Biotechnology Magazine.

Polpharma Biologics and MS Pharma Sign Licensing Agreements for ...

Polpharma Biologics and MS Pharma partner to expand biosimilar access

Deal covers biosimilars for gastroenterology, neurology and dermatology